Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 20 of 20 publications.
Skip to main content
Midkiff K, Harris D, Gilsenan A, Andrews E. Studying cancer as an adverse outcome from nononcological therapies: review of the Food and Drug Administration's postmarketing commitment database. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.
Hauber AB, Gilsenan A, Juhaeri J, Zhong Y, Noel B. Benefit risk assessment: understanding and using patient preference methodologies. Presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.
Harris D, Gilsenan A, Harding A, Andrews E, Kellier N, Masica D. Long-term cancer surveillance: five-year update for the Forteo Patient Registry Surveillance Study. Poster presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2015. Boston, MA.
Harris DH, Gilsenan AW, Harding AA, DeGuire B, Andrews EB. Long-term cancer surveillance: five-year update for the Forteo Patient Registry data linkage study. Presented at the NAACCR 2015 Annual Conference; June 2015. Charlotte, NC. Previously presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Midkiff KD, Andrews EB, Gilsenan AW, Harris DH. "First in Flight" or "When Pigs Fly" – Can cancer registries play a critical role at the national level in studying cancer as an adverse outcome from drug treatments? Presented at the NAACCR 2015 Annual Conference; June 2015. Charlotte, NC.
Midkiff KD, Gilsenan AW, Andrews EB, Masica D, Ceberg J, Alvegard T. Findings from the postmarketing adult osteosarcoma surveillance study in the Nordic countries. Poster presented at the 37th Meeting of the Scandinavian Sarcoma Group; May 20, 2015. Stockholm, Sweden.
Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
Gilsenan AW. European guideline on Good Pharmacovigilance Practices (GVP) – Module XVI – risk minimization measures. Presented at the SCOPE Summit for Clinical Ops Executives; February 25, 2015. Orlando, FL.
Gilsenan AW. Observational data collection studies: considerations to minimize bias. Presented at the SCOPE Summit for Clinical Ops Executives; February 24, 2015. Orlando, FL.
Freeman E, Gilsenan AW. Assess the European guideline on good pharmacovigilance practices (GVP) – module XVI – risk minimization measures. Presented at the 7th Risk Evaluation and Mitigation Strategies Summit (REMS Summit); January 22, 2015. Arlington, VA.
Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang A. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007 Sep 1;61(9):1437-45.
Midkiff K, Gilsenan A, Martin R, Masica DN, Andrews E. Characteristics of patients in a postmarketing osteosarcoma surveillance study. Poster presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2007. Quebec City, Canada.
Gilsenan AW, Midkiff K, Wu Y, Martin R, Masica DN, Andrews E. Factors associated with interview completion rates in a surveillance study of osteosarcoma and antecedent exposures. Poster presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2007. Quebec City, Canada.
Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 21, 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug 7; 16(Suppl 2):S55. doi: 10.1002/pds.1461
Martin RD, Gilsenan AW, Wu Y, Midkiff KD, Masica DN. Long-term post-marketing studies: flexibility, perseverance and patience. Presented at the North American Association of Central Cancer Registries Annual Meeting; 2007.
Martin RD, Gilsenan AW, Midkiff KD, Wu Y, Andrews EB, Masica DN. Adult osteosarcoma surveillance study: results from a telephone survey with patients identified through central cancer registries. Presented at the North American Association of Central Cancer Registries Annual Meeting; 2007.
Martin RD, Gilsenan AW, Von Scheele BG. International drug safety monitoring using population-based cancer registries. Poster presented at the North American Association of Central Cancer Registries; 2007.
Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Assessing the impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Poster presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2007.
Naslund M, Gilsenan AW, Midkiff KD, Wolford E, Bown A, Wang J. The prevalence of luts and prostate enlargement in the primary care setting. Poster presented at the Annual Meeting of the American Urological Association; 2007.